[SCHEDULE 13G/A] BioMarin Pharmaceuticals Inc SEC Filing

Rhea-AI Filing Summary

Primecap Management Co/CA filed an amendment to Schedule 13G reporting beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock, equal to 8.24% of the class. The filing shows Primecap has sole voting power over 15,087,400 shares and sole dispositive power over 15,795,383 shares. The statement is for CUSIP 09061G101 and designates the security class as common stock. Item 10 certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is dated as an event on 06/30/2025 and signed on 08/13/2025.

Positive

• Reporting person discloses a material stake of 15,795,383 shares (8.24%) in BioMarin, exceeding the 5% reporting threshold
• Filing documents sole dispositive power over 15,795,383 shares, clarifying control of disposition for the position
• Item 10 certification states the position was acquired and is held in the ordinary course of business, not to influence control

Negative

• None.

Insights

Securities Analyst

TL;DR Primecap holds an 8.24% stake in BioMarin with sole dispositive control; disclosure is a material ownership update.

Primecap Management reports beneficial ownership of 15,795,383 shares (8.24%) of BioMarin common stock via a Schedule 13G/A. The filing documents sole voting power of 15,087,400 shares and sole dispositive power of 15,795,383 shares, indicating Primecap controls trading decisions for the position. The Item 10 certification states the position was acquired and is held in the ordinary course, not to influence control. For investors, this is a material ownership disclosure but not an operational change.

Corporate Governance Expert

TL;DR This Schedule 13G/A signals a sizable passive stake (8.24%) and confirms no declared intent to change issuer control.

The amendment clarifies Primecap's stake and voting/dispositive authority without indicating activist intent. The explicit certification that the shares were not acquired to influence control is important for governance assessment: it frames the holding as passive under the Schedule 13G framework. While the stake exceeds the 5% reporting threshold and is material, the filing contains no proposals, arrangements, or group affiliations that would suggest governance action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 25)

BioMarin Pharmaceutical Inc.

(Name of Issuer)

COM

(Title of Class of Securities)

09061G101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09061G101

1

Names of Reporting Persons

PRIMECAP MANAGEMENT CO/CA/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,087,400.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,795,383.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,795,383.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.24 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BioMarin Pharmaceutical Inc.
(b)	Address of issuer's principal executive offices: 770 Lindaro Street, San Rafael, CALIFORNIA 94901
Item 2.
(a)	Name of person filing: PRIMECAP MANAGEMENT CO/CA/
(b)	Address or principal business office or, if none, residence: 177 EAST COLORADO BLVD. 11TH FLOOR PASADENA, California 91105
(c)	Citizenship: PRIMECAP MANAGEMENT CO/CA/ - UNITED STATES
(d)	Title of class of securities: COM
(e)	CUSIP No.: 09061G101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15,795,383
(b)	Percent of class: 8.24 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: PRIMECAP MANAGEMENT CO/CA/ - 15,087,400
	(ii) Shared power to vote or to direct the vote: PRIMECAP MANAGEMENT CO/CA/ - 0
	(iii) Sole power to dispose or to direct the disposition of: PRIMECAP MANAGEMENT CO/CA/ - 15,795,383
	(iv) Shared power to dispose or to direct the disposition of: PRIMECAP MANAGEMENT CO/CA/ - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PRIMECAP MANAGEMENT CO/CA/

Signature:	Jorge A. Rodriguez
Name/Title:	Deputy Chief Compliance Officer
Date:	08/13/2025

FAQ

What stake does Primecap Management report in BioMarin (BMRN)?

Primecap reports beneficial ownership of 15,795,383 shares, representing 8.24% of BioMarin common stock.

How much voting power does Primecap have over BioMarin shares?

The filing shows Primecap has sole voting power over 15,087,400 shares and shared voting power of 0 shares.

Does Primecap have power to dispose of the BioMarin shares?

Yes. The filing reports sole dispositive power over 15,795,383 shares and shared dispositive power of 0 shares.

What does the filing say about Primecap's intent regarding control of BioMarin?

Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.

What form and dates are shown on this disclosure for BMRN?

This is an amendment to Schedule 13G (Amendment No. 25) reporting a triggering event date of 06/30/2025 and signed on 08/13/2025.